A nutrition formula milk powder for infants after congenital heart disease surgery or non-cardiac surgery and critically ill infants in intensive care. The nutrition formula milk powder has an energy to protein ratio of 55-60 kcal:3.0-4.0 g/100 ml.

A nutrition formula milk powder for infants after congenital heart disease surgery or non-cardiac surgery and critically ill infants in intensive care. The nutrition formula milk powder has an energy to protein ratio of 55-60 kcal:3.0-4.0 g/100 ml.

Methods of making a powdered milk product are described. The methods may include providing an aqueous milk-sourced mixture, and evaporating water from the aqueous milk-sourced mixture to produce an evaporated milk-sourced mixture having a total solids concentration of 35 wt. % or more. The evaporated milk-sourced mixture may be dried to form the powdered milk product, which may have less than 6 wt. % water. Systems for making the milk powdered product are also described. The systems may include an evaporator to evaporate water from a supply of a milk-sourced mixture to form an evaporated milk-sourced mixture. They may also include a dryer to dry the evaporated milk-sourced mixture and atomize it into the powdered milk product.

A solid composition, including the following components (A), (B) and (C): (A) 0.15 mass % or more and 3.0 mass % or less of a milk-derived sphingomyelin, (B) a sugar alcohol, and (C) potassium. Where a mass ratio of the component (C) to the component (A), [(C)/(A)], is from 0.2 to 9.0.

A solid composition, including the following components (A), (B) and (C): (A) 0.15 mass % or more and 3.0 mass % or less of a milk-derived sphingomyelin, (B) a sugar alcohol, and (C) potassium. Where a mass ratio of the component (C) to the component (A), [(C)/(A)], is from 0.2 to 9.0.

Provided is a technique that makes it possible to promote proliferation of probiotics having a low ability to assimilate human milk oligosaccharides (HMOs), in the presence of HMOs. Also provided is a nutritional composition containing bacteria belonging to Bifidobacterium bifidum, one or more types of probiotics having a low ability to assimilate human milk oligosaccharides, and human milk oligosaccharides. The nutritional composition according to the present technology may be suitably used for foods/drinks, medicines, quasi-drugs, feeds, and the like.

Provided is a method of optimizing animal colostrum for human consumption by removing allergenic components and combining one or more immune factors to enable the composition to target the mucosal barriers, thereby enhancing mucosal integrity and increasing immune support. The composition is purified to remove one or more of lactose, casein proteins, fats, and/or oils, thereby creating a product that is devoid of allergenic components. The composition may be combined with a prebiotic, and/or natural sweeteners, additional vitamins, herbs, and/or minerals, and flavoring ingredients. The resulting product forms an instantly dissolvable powder that can be distributed in single serve packets, aerosolized spray, and/or in a chewable form. Furthermore, the composition can be used as an ingredient in food and beverages, in infant formula, in medical foods, or in over-the-counter drugs. Also provided is a method of manufacturing the bioactive composition.

Provided is a method of optimizing animal colostrum for human consumption by removing allergenic components and combining one or more immune factors to enable the composition to target the mucosal barriers, thereby enhancing mucosal integrity and increasing immune support. The composition is purified to remove one or more of lactose, casein proteins, fats, and/or oils, thereby creating a product that is devoid of allergenic components. The composition may be combined with a prebiotic, and/or natural sweeteners, additional vitamins, herbs, and/or minerals, and flavoring ingredients. The resulting product forms an instantly dissolvable powder that can be distributed in single serve packets, aerosolized spray, and/or in a chewable form. Furthermore, the composition can be used as an ingredient in food and beverages, in infant formula, in medical foods, or in over-the-counter drugs. Also provided is a method of manufacturing the bioactive composition.

A method of producing a low-lactose milk protein concentrate comprising the steps of providing a starting liquid milk protein concentrate, pre-treating the milk protein concentration by ultra-sonication, and treating the pre-treated milk protein concentration by diafiltration to provide a calcium depleted low-lactose milk protein concentrate. The process of the invention provides a milk protein concentrate with high levels of protein, less than 1% lactose, and a calcium level that is depleted by at least 20% compared with an untreated milk protein concentrate.

A method of producing a low-lactose milk protein concentrate comprising the steps of providing a starting liquid milk protein concentrate, pre-treating the milk protein concentration by ultra-sonication, and treating the pre-treated milk protein concentration by diafiltration to provide a calcium depleted low-lactose milk protein concentrate. The process of the invention provides a milk protein concentrate with high levels of protein, less than 1% lactose, and a calcium level that is depleted by at least 20% compared with an untreated milk protein concentrate.